Merck Sharp + Dohme Corp.

Mochida Pharmaceutical Co., Ltd.

Mochida Pharmacuetical Co., Ltd.

John Qiang Tan

William J Greenlee

Samuel Chackalamannil

James M Balkovec

Dong-Ming Shen

Liangqin Guo

Cameron James Smith

Yi-Heng Chen

Yili Chen

Tomokazu Hirabayashi

Kun Liu

Hong Shen

Peter J Sinclair

Zhicai Wu

Richard Thomas Beresis

Anthony K Ogawa

Robert J DeVita

Yuguang Wang

Ting Zhang

Ping Lan

Changhe Qi

Alejandro Crespo

Zhongxiang Sun

Rudrajit Mal

Ellen K Vande Bunte

Min Shu

Mika Sekioka

Andrew William Stamford

Ronald M Kim

Derun Li

Tin-Yau Chan

Jiayi Xu

Kevin D Dykstra

Edward C Sherer

Hiroshi Nagasue

Louis-Charles Campeau

Timothy A Cernak

Kouki Ogawa

John W Mirc

William John Greenlee

Francis Lee

Wen-Lian Wu

Zhiqiang Yang

Thimothy A Cernak

Mika Katsuno

Tin Yan Chan

Robert J Devita

The present invention provides compounds of Formula (I) and pharmaceutical compositions comprising compounds of Formula I, and methods for using compounds of Formula I for treating or preventing thromboses, embolisms, hypercoaguability or fibrotic changes.

Factor IXa inhibitors

The present invention provides a compound of Formula (I) wherein

The present invention provides a compound of Formula (I) where A is a heterocycle ring system and B is a heterocycle ring system or aryl ring system, and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes.

The present invention is directed to compounds of the Formula I: as well as pharmaceutically acceptable salts thereof, that may be useful for treating aldosterone-mediated diseases. The invention furthermore relates to specific diastereomers and enantiomers of the compounds, to processes for preparing compounds of the Formula I, to their potential use for the therapy and prophylaxis of the above-mentioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of the Formula I. 

Mineralocorticoid receptor antagonists

The present invention is directed to compounds of the Formula I as well as pharmaceutically acceptable salts thereof, that are useful for treating aldosterone-mediated diseases. The invention furthermore relates to processes for preparing compounds of the Formula I, to their use for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of the Formula I.

Disclosed are the compounds of the Formula (I) as well as pharmaceutically acceptable salts thereof, which are useful for treating aldosterone-mediated diseases. The processes for preparing compounds of the Formula (I), the use for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and the pharmaceutical compositions which comprise compounds of the formula (I) are disclosed too. 

This inventions relates to compounds having the structure Formula I and pharmaceutically acceptable salts thereof which are soluble guanylate cyclase activators. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver. 

Soluble guanylate cyclase activators

Growing community of inventors

Westfield, NJ, United States of America

John Qiang Tan